12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Company News  |  Deals

Regulus, AstraZeneca deal

Regulus said that AstraZeneca selected an undisclosed cancer target under a 2012 deal to develop and commercialize preclinical microRNA therapeutics against three targets focused on cardiovascular...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >